AU2009221083B2 - Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 - Google Patents

Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 Download PDF

Info

Publication number
AU2009221083B2
AU2009221083B2 AU2009221083A AU2009221083A AU2009221083B2 AU 2009221083 B2 AU2009221083 B2 AU 2009221083B2 AU 2009221083 A AU2009221083 A AU 2009221083A AU 2009221083 A AU2009221083 A AU 2009221083A AU 2009221083 B2 AU2009221083 B2 AU 2009221083B2
Authority
AU
Australia
Prior art keywords
carbon atoms
group
hydrogen
alkyl group
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009221083A
Other languages
English (en)
Other versions
AU2009221083A1 (en
Inventor
Nicola Cazzolla
Guido Furlotti
Barbara Garofalo
Angelo Guglielmotti
Giorgina Mangano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of AU2009221083A1 publication Critical patent/AU2009221083A1/en
Application granted granted Critical
Publication of AU2009221083B2 publication Critical patent/AU2009221083B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
AU2009221083A 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 Ceased AU2009221083B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425139 2008-03-07
EP08425139.6 2008-03-07
PCT/EP2009/052585 WO2009109613A2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40

Publications (2)

Publication Number Publication Date
AU2009221083A1 AU2009221083A1 (en) 2009-09-11
AU2009221083B2 true AU2009221083B2 (en) 2013-11-28

Family

ID=39671487

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009221083A Ceased AU2009221083B2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
AU2009221089A Ceased AU2009221089B2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009221089A Ceased AU2009221089B2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40

Country Status (25)

Country Link
US (3) US7919518B2 (enExample)
EP (3) EP3181551A1 (enExample)
JP (2) JP5509099B2 (enExample)
KR (2) KR101599867B1 (enExample)
CN (2) CN101945855B (enExample)
AR (2) AR070810A1 (enExample)
AU (2) AU2009221083B2 (enExample)
BR (2) BRPI0907976A2 (enExample)
CA (2) CA2712703C (enExample)
CY (2) CY1117584T1 (enExample)
DK (2) DK2254869T3 (enExample)
EA (2) EA019711B1 (enExample)
ES (2) ES2569330T3 (enExample)
GE (2) GEP20135983B (enExample)
HR (2) HRP20171208T1 (enExample)
HU (1) HUE027098T2 (enExample)
IL (3) IL206893A0 (enExample)
LT (1) LT2254869T (enExample)
MX (2) MX2010009626A (enExample)
PL (2) PL2254870T3 (enExample)
PT (1) PT2254869T (enExample)
SG (1) SG188177A1 (enExample)
SI (2) SI2254869T1 (enExample)
UA (2) UA103605C2 (enExample)
WO (2) WO2009109613A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009625A (es) * 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
EA018185B1 (ru) 2008-03-07 2013-06-28 Ацьенде Кимике Рьюните Анджелини Франческо A.К.P.A.Ф. С.П.А. Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 или cx3cr1
DK2254869T3 (en) * 2008-03-07 2017-09-04 Acraf 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
BR112012002130A2 (pt) 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CA3095012C (en) * 2012-05-01 2023-02-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
DK2882715T3 (en) 2012-05-18 2017-02-13 Sanofi Sa PYRAZOL DERIVATIVES AND USE THEREOF AS LPAR5 ANTAGONISTS
JP2015521183A (ja) 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
US20140134116A1 (en) 2012-11-09 2014-05-15 Colgate-Palmolive Company Block Copolymers For Tooth Enamel Protection
EP3142664B1 (en) * 2014-05-15 2019-12-04 Translatum Medicus Inc. Compositions and methods for treating and diagnosing ocular disorders
AU2016277126A1 (en) * 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
US20180221339A1 (en) * 2015-06-16 2018-08-09 Translatum Medicus, Inc. Compositions and methods for treating and diagnosing ocular disorders
BR112019011825A2 (pt) 2016-12-12 2019-10-22 Vettore, LLC composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026570A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
EP3990433B1 (en) * 2019-06-25 2026-05-20 Translatum Medicus Inc. PROCESSES FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
FR3101358A1 (fr) * 2019-09-27 2021-04-02 Bioaster Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法
WO2024108386A1 (zh) * 2022-11-22 2024-05-30 中国科学院深圳先进技术研究院 抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用
EP4662203A1 (en) * 2023-02-10 2025-12-17 Translatum Medicus Inc. Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382276A2 (en) * 1989-02-07 1990-08-16 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids
EP0510748A1 (en) * 1991-04-22 1992-10-28 ANGELINI RICERCHE S.p.A. SOCIETA' CONSORTILE Use of a methoxy alkanoic acid of indazole for the manufacture of a medicament for the treatment of autoimmune diseases
WO1999004770A2 (en) * 1997-07-28 1999-02-04 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (Trading also as ACRAF S.P.A.) A pharmaceutical composition active in reducing production of mcp-1 protein

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US364371A (en) * 1887-06-07 peice
US416359A (en) * 1889-12-03 Sash-fastener
EP1185528A4 (en) 1999-06-17 2003-03-26 Shionogi Biores Corp INHIBITORS OF IL-12 PRODUCTION
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
JP4234439B2 (ja) 2001-03-15 2009-03-04 生化学工業株式会社 Ｉｌ−１２発現調節剤
BR0214809A (pt) 2001-11-30 2004-09-14 Synta Pharmaceuticals Corp Compostos de pirimidina
WO2005033115A1 (en) 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
EP1806145B1 (en) * 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
JP2008519850A (ja) 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
AU2005310143A1 (en) 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
DK2254869T3 (en) 2008-03-07 2017-09-04 Acraf 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
EA018185B1 (ru) 2008-03-07 2013-06-28 Ацьенде Кимике Рьюните Анджелини Франческо A.К.P.A.Ф. С.П.А. Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 или cx3cr1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382276A2 (en) * 1989-02-07 1990-08-16 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids
EP0510748A1 (en) * 1991-04-22 1992-10-28 ANGELINI RICERCHE S.p.A. SOCIETA' CONSORTILE Use of a methoxy alkanoic acid of indazole for the manufacture of a medicament for the treatment of autoimmune diseases
WO1999004770A2 (en) * 1997-07-28 1999-02-04 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (Trading also as ACRAF S.P.A.) A pharmaceutical composition active in reducing production of mcp-1 protein

Also Published As

Publication number Publication date
KR20100133957A (ko) 2010-12-22
IL207131A0 (en) 2010-12-30
IL215579A (en) 2015-06-30
DK2254870T3 (en) 2016-05-17
US8835481B2 (en) 2014-09-16
CA2712403C (en) 2017-06-06
CY1117584T1 (el) 2017-04-26
HRP20160462T1 (hr) 2016-06-03
IL215579A0 (en) 2011-11-30
JP5509099B2 (ja) 2014-06-04
AR070811A1 (es) 2010-05-05
IL206893A0 (en) 2010-12-30
EA019711B1 (ru) 2014-05-30
JP5509101B2 (ja) 2014-06-04
US8283348B2 (en) 2012-10-09
UA103605C2 (en) 2013-11-11
AU2009221089B2 (en) 2013-12-05
AR070810A1 (es) 2010-05-05
KR101581828B1 (ko) 2015-12-31
MX2010009626A (es) 2010-12-20
PT2254869T (pt) 2017-07-18
KR20100131432A (ko) 2010-12-15
GEP20135983B (en) 2013-12-10
EA018241B1 (ru) 2013-06-28
CN101945855A (zh) 2011-01-12
EP2254869A2 (en) 2010-12-01
BRPI0907976A2 (pt) 2015-08-04
WO2009109613A2 (en) 2009-09-11
PL2254869T3 (pl) 2017-10-31
BRPI0907977A2 (pt) 2015-08-04
US20110003874A1 (en) 2011-01-06
SI2254870T1 (sl) 2016-05-31
SG188177A1 (en) 2013-03-28
MX2010009623A (es) 2010-09-28
CN101952256A (zh) 2011-01-19
UA105170C2 (en) 2014-04-25
CY1119252T1 (el) 2018-02-14
HRP20171208T1 (hr) 2017-10-06
EP2254870B1 (en) 2016-02-24
IL207131A (en) 2013-02-28
EP2254870A2 (en) 2010-12-01
US20110160205A1 (en) 2011-06-30
CA2712703A1 (en) 2009-09-11
WO2009109618A2 (en) 2009-09-11
US20100311744A1 (en) 2010-12-09
ES2569330T3 (es) 2016-05-10
AU2009221089A1 (en) 2009-09-11
SI2254869T1 (sl) 2017-10-30
HUE027098T2 (en) 2016-08-29
JP2011513367A (ja) 2011-04-28
GEP20135912B (en) 2013-08-26
DK2254869T3 (en) 2017-09-04
EA201071038A1 (ru) 2011-02-28
AU2009221083A1 (en) 2009-09-11
US7919518B2 (en) 2011-04-05
LT2254869T (lt) 2017-08-10
CN101945855B (zh) 2014-12-17
WO2009109618A3 (en) 2009-12-10
PL2254870T3 (pl) 2016-07-29
CA2712403A1 (en) 2009-09-11
ES2637009T3 (es) 2017-10-10
CA2712703C (en) 2016-10-11
EP3181551A1 (en) 2017-06-21
EA201071040A1 (ru) 2011-02-28
KR101599867B1 (ko) 2016-03-04
JP2011513365A (ja) 2011-04-28
EP2254869B1 (en) 2017-05-31
CN101952256B (zh) 2016-03-16
WO2009109613A3 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
CA2712403C (en) Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
CA2714436C (en) Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
HK1235053A1 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 and p40
HK1148015B (en) Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 and p40
HK1148015A (en) Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 and p40
HK1145323B (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired